Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Source of Factor VIII Replacement (PLASMATIC OR RECOMBINANT) and Incidence of Inhibitory Alloantibodies in Previously Untreated Patients with Severe Hemophilia a: The Multicenter Randomized Sippet Study

Flora Peyvandi, MD PhD, Pier Mannuccio Mannucci, MD, Isabella Garagiola, PhD, Mohsen Elalfy, MD, Amal El-Beshlawy, MD, Madatha V. Ramanan, MD, Peyman Eshghi, MD, Suresh Hanagavadi, Ramabadran Varadarajan, MD, Mehran Karimi, MD, Mamta V. Manglani, MD, Cecil Ross, MD, Guy Young, MD, Tulika Seth, MD, Shashikant Apte, MD FRCPA, Dinesh M. Nayak, MD, Adriana C. Sandoval Gonzales, MD, Elena Santagostino, MD PhD, Maria Elisa Mancuso, MD PhD, Johnny N. Mahlangu, MD, Santiago Bonanad, PhD, Monica Cerqueira, MD, Nadia P. Ewing, MD, Christoph Male, MD MSC, Tarek Owaidah, MD FRCPA, Veronica Soto Arellano, MD, Nathan L. Kobrinsky, MD FRCP, Suvankar Majumdar, MD, Rosario Perez Garrido, MD, Anupam Sachdeva, Mindy Simpson, MD FAAP, Mathew Thomas, Ezio Zanon, MD, ALI Bulent Antmen, Kaan Kavakli, MD, Marilyn Manco-Johnson, MD, Monica Martinez, MD, Esperanza Marzouka, MS, PS, Maria Gabriella Mazzucconi, MD, Daniela Neme, MD, Angeles Palomo Bravo, MD, Rogelio Paredes Aguilera, MD, Alessandra Nunes Loureiro Prezotti, MD, Schmitt Klaus, MD, Brian M. Wicklund, MD MPH, Bulent Zulfikar, MD, Rosendaal R. Frits, MD PhD

Blood (2015) 126 (23): 5.

https://doi.org/10.1182/blood.V126.23.5.5

Published: 2015

Journal Articles

Relative Trends in Myocardial T2* Versus Myocardial Iron Concentration As Representations of Myocardial Iron Chelation Efficacy in Patients with β Thalassemia Major Treated with Deferasirox for up to 3 Years

John B Porter, MD, Ali T Taher, MD, Yesim Aydinok, MD, Amal El-Beshlawy, MD/Professor, Mohsen Elalfy, MD, Ali El-Ali, MD, Nathalie Barbier, M Domenica Cappellini, MD

Blood (2014) 124 (21): 4040.

https://doi.org/10.1182/blood.V124.21.4040.4040

Published: 2014

Journal Articles

Insights into Relationships Between Serum Ferritin and Liver Iron Concentration Trends during 12 Months of Iron Chelation Therapy with Deferasirox – a Post-Hoc Analysis from the Epic Study

John B Porter, MD, Mohsen Elalfy, MD, Ali T Taher, MD, Lee Lee Chan, MD, Szu-Hee Lee, MD, Pranee Sutcharitchan, MD, Yesim Aydinok, MD, Subhashish Chakravarty, PhD, Ali El-Ali, MD, Amal El-Beshlawy, MD/Professor

Blood (2014) 124 (21): 52.

https://doi.org/10.1182/blood.V124.21.52.52

Published: 2014

Journal Articles

Deferasirox–Deferoxamine Combination Therapy Reduces Cardiac Iron With Rapid Liver Iron Removal In Patients With Severe Transfusional Iron Overload (HYPERION)

Yesim Aydinok, MD, Antonis Kattamis, MD, M Domenica Cappellini, MD, Amal El-Beshlawy, MD, Raffaella Origa, MD, Mohsen Elalfy, MD, Yurdanur Kilinç, MD, Silverio Perrotta, MD, Zeynep Karakas, MD, Vip Viprakasit, MD, Dany Habr, MD, Antje Wegener, MD, Junwu Shen, PhD, John B Porter, MD

Blood (2013) 122 (21): 2257.

https://doi.org/10.1182/blood.V122.21.2257.2257

Published: 2013

Journal Articles

Deferasirox Compared With Deferoxamine For The Removal Of Cardiac Iron In Patients With β-Thalassemia Major: 2-Year Data From The Cordelia Extension

Dudley J Pennell, MD, John B Porter, MD, Antonio Piga, MD, Yongrong Lai, MD, Amal El-Beshlawy, MD, Khawla Belhoul, MD, Mohsen Elalfy, MD, Akif Yesilipek, MD, Yurdanur Kilinç, MD, Antje Wegener, MD, Dany Habr, MD, Junwu Shen, PhD, Yesim Aydinok, MD

Blood (2013) 122 (21): 1018.

https://doi.org/10.1182/blood.V122.21.1018.1018

Published: 2013

Journal Articles

Deferasirox Treatment for up to 3 Years in Iron-Overloaded Pediatric Patients Reduces Serum Ferritin with a Manageable Safety Profile

Amal El-Beshlawy, MD, Mohsen Elalfy, MD, Lee Lee Chan, MD, Yongrong Lai, MD, Kai-Hsin Lin, MD, Yesim Aydinok, MD, Renzo Galanello, MD, Ali El-Ali, MD, Nicolas Martin, MS, M Domenica Cappellini, MD

Blood (2012) 120 (21): 1028.

https://doi.org/10.1182/blood.V120.21.1028.1028

Published: 2012

Journal Articles

A Multicenter, Randomized, Open-Label Trial Evaluating Deferasirox Compared with Deferoxamine for the Removal of Cardiac Iron in Patients with β-Thalassemia Major and Iron Overload (CORDELIA).

Dudley J Pennell, MD, John B Porter, MD, Antonio Piga, MD, Yongrong Lai, MD, Amal El-Beshlawy, MD, Khawla Beloul, MD, Mohsen Elalfy, MD, Akif Yesilipek, MD, Yurdanur Kilinç, MD, Tomasz Lawniczek, MD, Dany Habr, MD, Marianne Weisskopf, PhD, Yiyun Zhang, PhD, Yesim Aydinok, MD

Blood (2012) 120 (21): 2124.

https://doi.org/10.1182/blood.V120.21.2124.2124

Published: 2012

Journal Articles

Serum Ferritin, Labile Plasma Iron and Transferrin Saturation: Comparison Between Underlying Anemias with Transfusional Iron Overload Before and After Treatment with Deferasirox.

John B Porter, MD, Mohsen Elalfy, MD, Vip Viprakasit, MD, DPhil, Stephane Giraudier, MD, Lee Lee Chan, MD, Yongrong Lai, MD, Ali El-Ali, MD, Nicolas Martin, MS, M Domenica Cappellini, MD

Blood (2012) 120 (21): 2126.

https://doi.org/10.1182/blood.V120.21.2126.2126

Published: 2012

NARROW

Source of Factor VIII Replacement (PLASMATIC OR RECOMBINANT) and Incidence of Inhibitory Alloantibodies in Previously Untreated Patients with Severe Hemophilia a: The Multicenter Randomized Sippet Study

Relative Trends in Myocardial T2* Versus Myocardial Iron Concentration As Representations of Myocardial Iron Chelation Efficacy in Patients with β Thalassemia Major Treated with Deferasirox for up to 3 Years

Insights into Relationships Between Serum Ferritin and Liver Iron Concentration Trends during 12 Months of Iron Chelation Therapy with Deferasirox – a Post-Hoc Analysis from the Epic Study

Deferasirox–Deferoxamine Combination Therapy Reduces Cardiac Iron With Rapid Liver Iron Removal In Patients With Severe Transfusional Iron Overload (HYPERION)

Deferasirox Compared With Deferoxamine For The Removal Of Cardiac Iron In Patients With β-Thalassemia Major: 2-Year Data From The Cordelia Extension

Deferasirox Treatment for up to 3 Years in Iron-Overloaded Pediatric Patients Reduces Serum Ferritin with a Manageable Safety Profile

A Multicenter, Randomized, Open-Label Trial Evaluating Deferasirox Compared with Deferoxamine for the Removal of Cardiac Iron in Patients with β-Thalassemia Major and Iron Overload (CORDELIA).

Serum Ferritin, Labile Plasma Iron and Transferrin Saturation: Comparison Between Underlying Anemias with Transfusional Iron Overload Before and After Treatment with Deferasirox.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only